3CTLP1-TATA for COVID-19

3CTLP1-TATA has been reported as potentially beneficial for COVID-19 in the following study.

COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed 3CTLP1-TATA in detail.

Study suggesting benefit with 3CTLP1-TATA

Sharif et al., Bicyclic temporin L peptide inhibitors targeting the SARS-CoV-2 main protease: design, synthesis, in vitro inhibition efficiency and molecular dynamics insights, RSC Medicinal Chemistry, doi:10.1039/d5md00528k

TBMB linker containing bicyclic temporin L peptide with three cysteine residues. 3D structure of the bicyclic peptide and its interaction with the main protease of SARS-CoV-2.